AIM: To characterize the population treated with SBRT for early-stage primary lung tumors in our institution, determine their outcomes, and identify potential prognosis factors. BACKGROUND: Stereotactic radiotherapy (SBRT) is an alternative treatment for inoperable patients with early-stage lung cancer. It confers a local control rate around 90% at 3 years, and 2-3 year overall survival rates of 43-60% in this population. MATERIALS AND METHODS: We retrospectively analyzed all patients treated in our department between 2012 and 2017 and evaluated local progression-free survival (L-PFS), nodal or distant progression-free survival (ND-PFS), global progression-free survival (G-PFS), overall survival (OS), and disease specific survival (DSS). Univariate (UVA) and multivariate (MVA) models were built to assess the influence of each variable. RESULTS: We identified 218 patients with 233 tumors. Most were male (78.9%) with a median age of 73 years. Median follow-up was 22 months. At 18 months, L-PFS was 93.7%, ND-PFS was 82.2%, G-PFS was 76.0%, DSS was 90.5%, and OS was 78.0% in ≤ T2 tumors. On UVA, T2 tumors were associated with lower L-PFS, G-PFS and DSS than T1, with no significant impact on ND-PFS or OS, an effect that persisted on MVA. On UVA, L-PFS and G-PFS were negatively influenced by female gender and a 5-fraction schedule was associated with worse G-PFS, which was not confirmed on MVA. CONCLUSION: Our local and distant control rates and survival were similar to those previously reported. On MVA, T2 tumors displayed lower L-PFS, G-PFS and DSS, with no difference in OS.
AIM: To characterize the population treated with SBRT for early-stage primary lung tumors in our institution, determine their outcomes, and identify potential prognosis factors. BACKGROUND: Stereotactic radiotherapy (SBRT) is an alternative treatment for inoperable patients with early-stage lung cancer. It confers a local control rate around 90% at 3 years, and 2-3 year overall survival rates of 43-60% in this population. MATERIALS AND METHODS: We retrospectively analyzed all patients treated in our department between 2012 and 2017 and evaluated local progression-free survival (L-PFS), nodal or distant progression-free survival (ND-PFS), global progression-free survival (G-PFS), overall survival (OS), and disease specific survival (DSS). Univariate (UVA) and multivariate (MVA) models were built to assess the influence of each variable. RESULTS: We identified 218 patients with 233 tumors. Most were male (78.9%) with a median age of 73 years. Median follow-up was 22 months. At 18 months, L-PFS was 93.7%, ND-PFS was 82.2%, G-PFS was 76.0%, DSS was 90.5%, and OS was 78.0% in ≤ T2 tumors. On UVA, T2 tumors were associated with lower L-PFS, G-PFS and DSS than T1, with no significant impact on ND-PFS or OS, an effect that persisted on MVA. On UVA, L-PFS and G-PFS were negatively influenced by female gender and a 5-fraction schedule was associated with worse G-PFS, which was not confirmed on MVA. CONCLUSION: Our local and distant control rates and survival were similar to those previously reported. On MVA, T2 tumors displayed lower L-PFS, G-PFS and DSS, with no difference in OS.
Authors: Neal E Dunlap; James M Larner; Paul W Read; Benjamin D Kozower; Christine L Lau; Ke Sheng; David R Jones Journal: J Thorac Cardiovasc Surg Date: 2010-05-15 Impact factor: 5.209
Authors: Andrea Bezjak; Rebecca Paulus; Laurie E Gaspar; Robert D Timmerman; William L Straube; William F Ryan; Yolanda I Garces; Anthony T Pu; Anurag K Singh; Gregory M Videtic; Ronald C McGarry; Puneeth Iyengar; Jason R Pantarotto; James J Urbanic; Alexander Y Sun; Megan E Daly; Inga S Grills; Paul Sperduto; Daniel P Normolle; Jeffrey D Bradley; Hak Choy Journal: J Clin Oncol Date: 2019-04-03 Impact factor: 44.544
Authors: Vivek Verma; Valerie K Shostrom; Sameera S Kumar; Weining Zhen; Christopher L Hallemeier; Steve E Braunstein; John Holland; Matthew M Harkenrider; Adrian S Iskhanian; Hanmanth J Neboori; Salma K Jabbour; Albert Attia; Percy Lee; Fiori Alite; Joshua M Walker; John M Stahl; Kyle Wang; Brian S Bingham; Christina Hadzitheodorou; Roy H Decker; Ronald C McGarry; Charles B Simone Journal: Cancer Date: 2016-10-14 Impact factor: 6.860
Authors: Meredith E Giuliani; Andrew Hope; Victor Mangona; Matthias Guckenberger; Frederick Mantel; Heike Peulen; Jan-Jakob Sonke; José Belderbos; Maria Werner-Wasik; Hong Ye; Inga S Grills Journal: Clin Lung Cancer Date: 2016-10-26 Impact factor: 4.785
Authors: P E Postmus; K M Kerr; M Oudkerk; S Senan; D A Waller; J Vansteenkiste; C Escriu; S Peters Journal: Ann Oncol Date: 2017-07-01 Impact factor: 32.976
Authors: Gaurav Marwaha; Kevin L Stephans; Neil M Woody; Chandana A Reddy; Gregory M M Videtic Journal: J Thorac Oncol Date: 2014-11 Impact factor: 15.609
Authors: Neil M Woody; Kevin L Stephans; Martin Andrews; Tingliang Zhuang; Priyanka Gopal; Ping Xia; Carol F Farver; Daniel P Raymond; Craig D Peacock; Joseph Cicenia; Chandana A Reddy; Gregory M M Videtic; Mohamed E Abazeed Journal: J Thorac Oncol Date: 2016-12-22 Impact factor: 15.609
Authors: Noëlle C van der Voort van Zyp; Jean-Briac Prévost; Mischa S Hoogeman; John Praag; Bronno van der Holt; Peter C Levendag; Robertus J van Klaveren; Peter Pattynama; Joost J Nuyttens Journal: Radiother Oncol Date: 2009-03-16 Impact factor: 6.280
Authors: Henry S Park; Frank C Detterbeck; David C Madoff; Brett C Bade; Ulas Kumbasar; Vincent J Mase; Andrew X Li; Justin D Blasberg; Gavitt A Woodard; Whitney S Brandt; Roy H Decker Journal: J Thorac Dis Date: 2022-06 Impact factor: 3.005